Comparison of Safety and Effectiveness between Levetiracetam and Phenytoin in the Treatment of Pediatric Status Epilepticus: A Meta- Analysis.

IF 2.7 4区医学 Q3 NEUROSCIENCES CNS & neurological disorders drug targets Pub Date : 2023-01-01 DOI:10.2174/1568007X04666220509215121

Qasem A AlMulihi, Fatimah A AlMuhanna, Mohammed A AlMuhanna, Eman A AlSultan

{"title":"Comparison of Safety and Effectiveness between Levetiracetam and Phenytoin in the Treatment of Pediatric Status Epilepticus: A Meta- Analysis.","authors":"Qasem A AlMulihi, Fatimah A AlMuhanna, Mohammed A AlMuhanna, Eman A AlSultan","doi":"10.2174/1568007X04666220509215121","DOIUrl":null,"url":null,"abstract":"Objective: To evaluate the safety and effectiveness of levetiracetam and phenytoin by evaluating the events of seizure termination and recurrence in children.Methods: We used the internet databases PubMed, Embase, and Google Scholar to conduct a literature search for the appropriate studies. A meta-analysis was performed to calculate the odds ratio using fixed and random-effects models.Results: We identified 15 studies that were eligible for the meta-analysis. The incidence of seizure termination within 24 h was 76.9% for levetiracetam and 70.5% for phenytoin. Levetiracetam had a higher number of seizure termination events than phenytoin (P = 0.005, I2 = 66%). The incidence of seizure recurrence within 24 h was 10% for levetiracetam and 15.6% for phenytoin. Phenytoin had a significantly higher number of seizure recurrence events than levetiracetam (P = 0.00007, I2 = 21%).Conclusion: The efficacy and safety of levetiracetam are superior to that of phenytoin in children with status epilepticus. Large Randomized Controlled Trial studies are needed to confirm the result in children.","PeriodicalId":10456,"journal":{"name":"CNS & neurological disorders drug targets","volume":null,"pages":null},"PeriodicalIF":2.7000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CNS & neurological disorders drug targets","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/1568007X04666220509215121","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"NEUROSCIENCES","Score":null,"Total":0}

引用次数: 1

Abstract

Objective: To evaluate the safety and effectiveness of levetiracetam and phenytoin by evaluating the events of seizure termination and recurrence in children.

Methods: We used the internet databases PubMed, Embase, and Google Scholar to conduct a literature search for the appropriate studies. A meta-analysis was performed to calculate the odds ratio using fixed and random-effects models.

Results: We identified 15 studies that were eligible for the meta-analysis. The incidence of seizure termination within 24 h was 76.9% for levetiracetam and 70.5% for phenytoin. Levetiracetam had a higher number of seizure termination events than phenytoin (P = 0.005, I² = 66%). The incidence of seizure recurrence within 24 h was 10% for levetiracetam and 15.6% for phenytoin. Phenytoin had a significantly higher number of seizure recurrence events than levetiracetam (P = 0.00007, I² = 21%).

Conclusion: The efficacy and safety of levetiracetam are superior to that of phenytoin in children with status epilepticus. Large Randomized Controlled Trial studies are needed to confirm the result in children.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

左乙拉西坦与苯妥英治疗儿童癫痫持续状态的安全性和有效性比较:荟萃分析。

目的:评价左乙拉西坦和苯妥英在小儿癫痫发作终止和复发中的安全性和有效性。方法:利用互联网数据库PubMed、Embase和Google Scholar进行文献检索，寻找合适的研究。采用固定效应和随机效应模型进行meta分析，计算优势比。结果:我们确定了15项符合meta分析的研究。左乙西坦24 h内癫痫发作终止率为76.9%，苯妥英为70.5%。左乙拉西坦的癫痫终止事件数高于苯妥英(P = 0.005, I2 = 66%)。左乙拉西坦组24 h内癫痫复发率为10%，苯妥英组为15.6%。苯妥英的癫痫复发次数明显高于左乙拉西坦(P = 0.00007, I2 = 21%)。结论:左乙拉西坦治疗癫痫持续状态患儿的疗效和安全性优于苯妥英。需要大型随机对照试验来证实儿童的结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

CNS & neurological disorders drug targets 医学-神经科学

CiteScore

5.10

自引率

3.30%

发文量

158

审稿时长

6-12 weeks

期刊介绍： Aims & Scope CNS & Neurological Disorders - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in neurological and central nervous system (CNS) disorders e.g. disease specific proteins, receptors, enzymes, genes. CNS & Neurological Disorders - Drug Targets publishes guest edited thematic issues written by leaders in the field covering a range of current topics of CNS & neurological drug targets. The journal also accepts for publication original research articles, letters, reviews and drug clinical trial studies. As the discovery, identification, characterization and validation of novel human drug targets for neurological and CNS drug discovery continues to grow; this journal is essential reading for all pharmaceutical scientists involved in drug discovery and development.